Neurocrine Biosciences, Inc. (0K6R.L)
USD 138.27
(1.59%)
USD 138.27
(1.59%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.01 Billion USD | 54.24% |
| 2022 | 660.9 Million USD | -5.38% |
| 2021 | 698.5 Million USD | 14.79% |
| 2020 | 608.5 Million USD | -9.06% |
| 2019 | 669.1 Million USD | 30.59% |
| 2018 | 512.38 Million USD | 15.03% |
| 2017 | 445.45 Million USD | 787.2% |
| 2016 | 50.2 Million USD | -0.24% |
| 2015 | 50.33 Million USD | 46.59% |
| 2014 | 34.33 Million USD | 0.2% |
| 2013 | 34.26 Million USD | -17.64% |
| 2012 | 41.6 Million USD | -46.85% |
| 2011 | 78.28 Million USD | -37.41% |
| 2010 | 125.07 Million USD | 87.06% |
| 2009 | 66.86 Million USD | -17.87% |
| 2008 | 81.4 Million USD | -48.46% |
| 2007 | 157.95 Million USD | 110.72% |
| 2006 | 74.96 Million USD | -19.41% |
| 2005 | 93.01 Million USD | -25.82% |
| 2004 | 125.39 Million USD | -23.47% |
| 2003 | 163.83 Million USD | 287.45% |
| 2002 | 42.28 Million USD | 17.6% |
| 2001 | 35.95 Million USD | 58.02% |
| 2000 | 22.75 Million USD | 77.77% |
| 1999 | 12.8 Million USD | 50.59% |
| 1998 | 8.5 Million USD | -2.3% |
| 1997 | 8.7 Million USD | 67.31% |
| 1996 | 5.2 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.08 Billion USD | 6.56% |
| 2024 Q2 | 795.8 Million USD | -26.74% |
| 2024 Q3 | 816.1 Million USD | 2.55% |
| 2023 Q3 | 846.1 Million USD | 11.31% |
| 2023 Q1 | 675.3 Million USD | 2.18% |
| 2023 Q4 | 1.01 Billion USD | 20.48% |
| 2023 Q2 | 760.1 Million USD | 12.56% |
| 2023 FY | 1.01 Billion USD | 54.24% |
| 2022 Q2 | 582.3 Million USD | -22.71% |
| 2022 Q4 | 660.9 Million USD | 10.37% |
| 2022 Q1 | 753.4 Million USD | 7.86% |
| 2022 FY | 660.9 Million USD | -5.38% |
| 2022 Q3 | 598.8 Million USD | 2.83% |
| 2021 FY | 698.5 Million USD | 14.79% |
| 2021 Q1 | 640.8 Million USD | 5.31% |
| 2021 Q2 | 677.2 Million USD | 5.68% |
| 2021 Q3 | 671.3 Million USD | -0.87% |
| 2021 Q4 | 698.5 Million USD | 4.05% |
| 2020 Q4 | 608.5 Million USD | -12.86% |
| 2020 FY | 608.5 Million USD | -9.06% |
| 2020 Q3 | 698.3 Million USD | 2.03% |
| 2020 Q2 | 684.4 Million USD | 3.45% |
| 2020 Q1 | 661.6 Million USD | -1.12% |
| 2019 Q1 | 548.44 Million USD | 7.04% |
| 2019 Q2 | 583.15 Million USD | 6.33% |
| 2019 Q3 | 605.42 Million USD | 3.82% |
| 2019 Q4 | 669.1 Million USD | 10.52% |
| 2019 FY | 669.1 Million USD | 30.59% |
| 2018 Q4 | 512.38 Million USD | 5.38% |
| 2018 Q1 | 441.87 Million USD | -0.8% |
| 2018 Q2 | 463.88 Million USD | 4.98% |
| 2018 Q3 | 486.23 Million USD | 4.82% |
| 2018 FY | 512.38 Million USD | 15.03% |
| 2017 Q1 | 42.22 Million USD | -15.91% |
| 2017 Q4 | 445.45 Million USD | 4.82% |
| 2017 Q3 | 424.98 Million USD | 3.95% |
| 2017 Q2 | 408.84 Million USD | 868.31% |
| 2017 FY | 445.45 Million USD | 787.2% |
| 2016 Q3 | 47.51 Million USD | -2.64% |
| 2016 Q4 | 50.2 Million USD | 5.68% |
| 2016 Q1 | 46.37 Million USD | -7.86% |
| 2016 FY | 50.2 Million USD | -0.24% |
| 2016 Q2 | 48.8 Million USD | 5.23% |
| 2015 Q2 | 44.26 Million USD | 2.82% |
| 2015 FY | 50.33 Million USD | 46.59% |
| 2015 Q3 | 45.49 Million USD | 2.77% |
| 2015 Q4 | 50.33 Million USD | 10.63% |
| 2015 Q1 | 43.04 Million USD | 25.38% |
| 2014 Q3 | 33.71 Million USD | 3.12% |
| 2014 Q2 | 32.69 Million USD | 1.41% |
| 2014 FY | 34.33 Million USD | 0.2% |
| 2014 Q1 | 32.23 Million USD | -5.92% |
| 2014 Q4 | 34.33 Million USD | 1.84% |
| 2013 Q4 | 34.26 Million USD | -6.57% |
| 2013 FY | 34.26 Million USD | -17.64% |
| 2013 Q3 | 36.67 Million USD | -5.47% |
| 2013 Q1 | 38.97 Million USD | -6.34% |
| 2013 Q2 | 38.79 Million USD | -0.45% |
| 2012 Q1 | 66.3 Million USD | -15.3% |
| 2012 Q2 | 57.35 Million USD | -13.5% |
| 2012 Q3 | 49.94 Million USD | -12.92% |
| 2012 Q4 | 41.6 Million USD | -16.7% |
| 2012 FY | 41.6 Million USD | -46.85% |
| 2011 FY | 78.28 Million USD | -37.41% |
| 2011 Q4 | 78.28 Million USD | -14.23% |
| 2011 Q3 | 91.27 Million USD | -10.38% |
| 2011 Q2 | 101.84 Million USD | -8.25% |
| 2011 Q1 | 111 Million USD | -11.25% |
| 2010 Q1 | 63.16 Million USD | -5.54% |
| 2010 FY | 125.07 Million USD | 87.06% |
| 2010 Q4 | 125.07 Million USD | -6.16% |
| 2010 Q3 | 133.28 Million USD | -6.55% |
| 2010 Q2 | 142.63 Million USD | 125.82% |
| 2009 Q4 | 66.86 Million USD | -10.65% |
| 2009 Q2 | 79.52 Million USD | -2.92% |
| 2009 FY | 66.86 Million USD | -17.87% |
| 2009 Q1 | 81.91 Million USD | 0.63% |
| 2009 Q3 | 74.83 Million USD | -5.9% |
| 2008 Q3 | 144.08 Million USD | -1.2% |
| 2008 FY | 81.4 Million USD | -48.46% |
| 2008 Q1 | 145.21 Million USD | -8.06% |
| 2008 Q2 | 145.82 Million USD | 0.42% |
| 2008 Q4 | 81.4 Million USD | -43.5% |
| 2007 Q4 | 157.95 Million USD | 117.74% |
| 2007 FY | 157.95 Million USD | 110.72% |
| 2007 Q3 | 72.54 Million USD | -0.37% |
| 2007 Q2 | 72.81 Million USD | 1.12% |
| 2007 Q1 | 72.01 Million USD | -3.93% |
| 2006 Q2 | 80.77 Million USD | -13.68% |
| 2006 FY | 74.96 Million USD | -19.41% |
| 2006 Q4 | 74.96 Million USD | -3.47% |
| 2006 Q1 | 93.57 Million USD | 0.6% |
| 2006 Q3 | 77.65 Million USD | -3.86% |
| 2005 Q3 | 97.22 Million USD | -6.05% |
| 2005 FY | 93.01 Million USD | -25.82% |
| 2005 Q1 | 111.64 Million USD | -10.96% |
| 2005 Q2 | 103.49 Million USD | -7.3% |
| 2005 Q4 | 93.01 Million USD | -4.33% |
| 2004 Q1 | 151.86 Million USD | -7.31% |
| 2004 Q3 | 140.05 Million USD | 3.79% |
| 2004 Q2 | 134.93 Million USD | -11.15% |
| 2004 Q4 | 125.39 Million USD | -10.47% |
| 2004 FY | 125.39 Million USD | -23.47% |
| 2003 FY | 163.83 Million USD | 287.45% |
| 2003 Q3 | 165.57 Million USD | 1.71% |
| 2003 Q2 | 162.79 Million USD | 10.12% |
| 2003 Q1 | 147.83 Million USD | 249.61% |
| 2003 Q4 | 163.83 Million USD | -1.05% |
| 2002 FY | 42.28 Million USD | 17.6% |
| 2002 Q3 | 38.81 Million USD | 13.7% |
| 2002 Q4 | 42.28 Million USD | 8.95% |
| 2002 Q2 | 34.13 Million USD | -0.63% |
| 2002 Q1 | 34.35 Million USD | -4.46% |
| 2001 Q4 | 35.95 Million USD | 10.91% |
| 2001 FY | 35.95 Million USD | 58.02% |
| 2001 Q1 | 19.54 Million USD | -14.1% |
| 2001 Q2 | 20.75 Million USD | 6.21% |
| 2001 Q3 | 32.42 Million USD | 56.18% |
| 2000 FY | 22.75 Million USD | 77.77% |
| 2000 Q1 | 14.36 Million USD | 12.2% |
| 2000 Q2 | 11.05 Million USD | -23.02% |
| 2000 Q3 | 14.82 Million USD | 34.1% |
| 2000 Q4 | 22.75 Million USD | 53.48% |
| 1999 Q1 | 6.6 Million USD | -22.35% |
| 1999 Q2 | 7.3 Million USD | 10.61% |
| 1999 Q3 | 9 Million USD | 23.29% |
| 1999 Q4 | 12.8 Million USD | 42.22% |
| 1999 FY | 12.8 Million USD | 50.59% |
| 1998 Q2 | 5.1 Million USD | -16.39% |
| 1998 Q4 | 8.5 Million USD | 3.66% |
| 1998 Q1 | 6.1 Million USD | -29.89% |
| 1998 FY | 8.5 Million USD | -2.3% |
| 1998 Q3 | 8.2 Million USD | 60.78% |
| 1997 Q2 | 6.6 Million USD | 15.79% |
| 1997 Q4 | 8.7 Million USD | 35.94% |
| 1997 Q1 | 5.7 Million USD | 9.62% |
| 1997 FY | 8.7 Million USD | 67.31% |
| 1997 Q3 | 6.4 Million USD | -3.03% |
| 1996 Q4 | 5.2 Million USD | 30.0% |
| 1996 Q2 | 4.9 Million USD | 25.64% |
| 1996 Q1 | 3.9 Million USD | 0.0% |
| 1996 FY | 5.2 Million USD | 0.0% |
| 1996 Q3 | 4 Million USD | -18.37% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -579.346% |
| Dynavax Technologies Corporation | 375.02 Million USD | -171.823% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -109.124% |
| Perrigo Company plc | 6.04 Billion USD | 83.126% |
| Illumina, Inc. | 4.36 Billion USD | 76.651% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 98.035% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -420.798% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 98.52% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 95.044% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -297.459% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 85.657% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -2633.562% |
| Waters Corporation | 3.47 Billion USD | 70.678% |
| Biogen Inc. | 12.04 Billion USD | 91.537% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -1136.641% |
| Evolus, Inc. | 209.68 Million USD | -386.153% |
| Adicet Bio, Inc. | 37.12 Million USD | -2646.228% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -1382.57% |
| bluebird bio, Inc. | 424.62 Million USD | -140.071% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -54.27% |
| FibroGen, Inc. | 585.72 Million USD | -74.04% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 79.272% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -2797.907% |
| Homology Medicines, Inc. | 118.53 Million USD | -760.014% |
| Geron Corporation | 146.12 Million USD | -597.612% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 74.833% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -65.03% |
| Myriad Genetics, Inc. | 312.9 Million USD | -225.791% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -4978.97% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -306.446% |
| Zoetis Inc. | 9.29 Billion USD | 89.033% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -1972.962% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 70.92% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 46.065% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 80.205% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -2004.242% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 60.843% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -285.064% |
| Verastem, Inc. | 71.18 Million USD | -1332.043% |
| Nektar Therapeutics | 267.04 Million USD | -281.732% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -156.608% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -2434.182% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 57.618% |
| OPKO Health, Inc. | 622.47 Million USD | -63.765% |
| Exelixis, Inc. | 678.44 Million USD | -50.255% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -787.886% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -8033.078% |
| uniQure N.V. | 624.01 Million USD | -63.36% |
| Imunon, Inc. | 8.53 Million USD | -11850.164% |
| Blueprint Medicines Corporation | 918.64 Million USD | -10.968% |
| Insmed Incorporated | 1.66 Billion USD | 38.655% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 38.198% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -708.412% |
| TG Therapeutics, Inc. | 169.08 Million USD | -502.892% |
| Incyte Corporation | 1.59 Billion USD | 35.978% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 14.018% |